NOVEL GALACTOSIDE INHIBITOR OF GALECTINS

The present invention relates to a compound of the general formula (I) wherein the pyranose ring is a-D-galactopyranose, R1 is selected from the group consisting of (II) wherein the asterix 1 * indicates the carbon atom of the heteroaromatic ring that is covalently attached to the triazole group of...

Full description

Saved in:
Bibliographic Details
Main Author ZETTERBERG, FREDRIK
Format Patent
LanguageEnglish
French
Published 18.07.2019
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a compound of the general formula (I) wherein the pyranose ring is a-D-galactopyranose, R1 is selected from the group consisting of (II) wherein the asterix 1 * indicates the carbon atom of the heteroaromatic ring that is covalently attached to the triazole group of formula (I). The compound of formula (I) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. La présente invention concerne un composé de formule générale (I) dans laquelle le cycle pyranose est un -D-galactopyranose, R1 est choisi dans le groupe constitué par (II), l'astérix 1 * indiquant l'atome de carbone du cycle hétéroaromatique qui est lié de manière covalente au groupe triazole de formule (I). Le composé de formule (1) est approprié pour être utilisé dans une méthode pour traiter un trouble associé à la liaison d'une galectine, comme la galectine-1, à un ligand chez un mammifère, comme l'être humain.
Bibliography:Application Number: CA20193086092